Anagliptin monotherapy in patients with type 2 diabetes mellitus and high low-density lipoprotein cholesterol reduces fasting plasma lathosterol level: a single-arm intervention trial
Yuichi Ikegami, View ORCID ProfileIkuo Inoue, View ORCID ProfileYasuhiro Takenaka, Daigo Saito, Mitsuhiko Noda, View ORCID ProfileAkira Shimada
doi: https://doi.org/10.1101/2020.05.16.20095307
Yuichi Ikegami
aDepartment of Endocrinology and Diabetes, Saitama Medical University, Faculty of Medicine, 38 Morohongo, Moroyamacho, Irumagun, Saitama 350-0495, Japan
MD, PhDIkuo Inoue
aDepartment of Endocrinology and Diabetes, Saitama Medical University, Faculty of Medicine, 38 Morohongo, Moroyamacho, Irumagun, Saitama 350-0495, Japan
MD, PhDYasuhiro Takenaka
aDepartment of Endocrinology and Diabetes, Saitama Medical University, Faculty of Medicine, 38 Morohongo, Moroyamacho, Irumagun, Saitama 350-0495, Japan
bDepartment of Physiology, Graduate School of Medicine, Nippon Medical School, 1-25-16 Nezu, Bunkyo, Tokyo 113-0031, Japan
PhDDaigo Saito
aDepartment of Endocrinology and Diabetes, Saitama Medical University, Faculty of Medicine, 38 Morohongo, Moroyamacho, Irumagun, Saitama 350-0495, Japan
MDMitsuhiko Noda
aDepartment of Endocrinology and Diabetes, Saitama Medical University, Faculty of Medicine, 38 Morohongo, Moroyamacho, Irumagun, Saitama 350-0495, Japan
MD, PhDAkira Shimada
aDepartment of Endocrinology and Diabetes, Saitama Medical University, Faculty of Medicine, 38 Morohongo, Moroyamacho, Irumagun, Saitama 350-0495, Japan
MD, PhDData Availability
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
Posted May 22, 2020.
Anagliptin monotherapy in patients with type 2 diabetes mellitus and high low-density lipoprotein cholesterol reduces fasting plasma lathosterol level: a single-arm intervention trial
Yuichi Ikegami, Ikuo Inoue, Yasuhiro Takenaka, Daigo Saito, Mitsuhiko Noda, Akira Shimada
medRxiv 2020.05.16.20095307; doi: https://doi.org/10.1101/2020.05.16.20095307
Anagliptin monotherapy in patients with type 2 diabetes mellitus and high low-density lipoprotein cholesterol reduces fasting plasma lathosterol level: a single-arm intervention trial
Yuichi Ikegami, Ikuo Inoue, Yasuhiro Takenaka, Daigo Saito, Mitsuhiko Noda, Akira Shimada
medRxiv 2020.05.16.20095307; doi: https://doi.org/10.1101/2020.05.16.20095307
Subject Areas
- Addiction Medicine (354)
- Allergy and Immunology (676)
- Anesthesia (182)
- Cardiovascular Medicine (2676)
- Dermatology (227)
- Emergency Medicine (404)
- Epidemiology (12304)
- Forensic Medicine (10)
- Gastroenterology (768)
- Genetic and Genomic Medicine (4149)
- Geriatric Medicine (389)
- Health Economics (684)
- Health Informatics (2688)
- Health Policy (1009)
- Hematology (365)
- HIV/AIDS (859)
- Medical Education (401)
- Medical Ethics (110)
- Nephrology (444)
- Neurology (3931)
- Nursing (212)
- Nutrition (584)
- Oncology (2068)
- Ophthalmology (592)
- Orthopedics (243)
- Otolaryngology (307)
- Pain Medicine (252)
- Palliative Medicine (75)
- Pathology (473)
- Pediatrics (1128)
- Primary Care Research (461)
- Public and Global Health (6572)
- Radiology and Imaging (1418)
- Respiratory Medicine (874)
- Rheumatology (413)
- Sports Medicine (345)
- Surgery (455)
- Toxicology (54)
- Transplantation (189)
- Urology (169)